To what extent do Artemisinin-Based Combination Therapies (ACTs),
Artemether-lumefantrine (AL), Artesunate-amodiaquine (AS-AQ),
Artesunate-sulfadoxine-pyrimethamine (AS-SP), Dihydroartemisinin-piperaquine
(DHA-PQ), and Artesunate-pyronaridine (AS-Py) effectively treat uncomplicated
Plasmodium falciparum (malaria) in patients under 16 years with HIV and in Burkina Faso,
Nigeria, Kenya, Tanzania, Uganda, Zambia, Ghana and Madagascar?
